Response to biologics in rheumatoid arthritis

Not Applicable

• Conditions: rheumatoid arthritis; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12613000123741
• Lead Sponsor: niversity of Otago, Christchurch

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-02-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

I.Male or female, aged >/=18 years, with Rheumatoid Arthritis as defined by the ACR Criteria (Aletaha et al. 2010) receiving or commencing any biologic therapy.
II.Able and willing to give written informed consent and to comply with the requirements of the study.

Exclusion Criteria

patients with serious uncontrolled chronic concomitant disease

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relationship between antidrug antibodies and disease activity. Disease activity will be assessed examination to determine using swollen and tender joint counts, calculation of disease activity score, and laboratory measurement of c reactive protein[A single timepoint between 4 and 6 months after starting biological therapy];Relationship between disease activity and drug concentrations.Disease activity will be assessed examination to determine using swollen and tender joint counts, calculation of disease activity score, and laboratory measurement of c reactive protein[A single timepoint between 4 and 6 months after starting biological therapy]

Secondary Outcome Measures

Name	Time	Method
nil[nil]